Abraxane shows efficacy for managing metastatic breast cancer
A noteworthy role was portrayed by thirty-eight affiliated medical centers of US Oncology, Inc. nationwide in helping Abraxane’s clinical research to get approved by the FDA.
Abraxane or paclitaxel protein-bound particles for injectable suspension is classified as the next-generation taxane; it is rated as first-of-its-kind in context of potential albumin-bound nanotechnology class, which has already been approved for helping patients afflicted with metastatic breast cancer.
From News-Medical.Net:
US Oncology conducted a phase 2 clinical trial of Abraxane in patients with metastatic breast cancer who were resistant to taxane drugs and continue to participate in the ongoing clinical development of the drug. Clinical trials of Abraxane have shown that the new drug is superior to solvent-based paclitaxel (commonly marketed as Taxol) in response rate and time to tumor progression.
“Abraxane is a significant advance in how paclitaxel is delivered and provides a much-needed new option for breast cancer patients,” said Joyce A. O’Shaughnessy, M.D., co-director, US Oncology Breast Cancer Research, and director, Breast Cancer Prevention, at Baylor-Charles A. Sammons Cancer Center in Dallas, Texas. “With this human protein nanoparticle form of paclitaxel, patients no longer require steroid premedication to avoid the sometimes life- threatening allergic reactions which occur with current solvent-based paclitaxel therapy.” “In our trials with weekly Abraxane, we saw fewer side effects than observed with solvent-based paclitaxel, and, even more encouraging, we saw a significant response to Abraxane in some women whose cancer had progressed through treatment with taxanes.
It is worthwhile to note here that patients with metastatic breast cancer are required to premedication involving usage of steroids and antihistamines (via slow infusions).
Tags: Abraxane, metastatic breast cancer, Steroids, taxane
Recent Comments